… Sorafenib (SOR) is the first line treatment for advanced hepatocellular carcinoma (HCC),
but resistance develops frequently. Tumor-associated macrophages (TAMs) have been …

… Sorafenib, a multi-kinase inhibitor with antiangiogenic, antiproliferative, and … late-stage
hepatocellular carcinoma (HCC). However, the therapeutic effect remains limited due to sorafenib …

… is managed by palliative systemic therapy in such cases, which in the past 10 years have
relied primarily on the tyrosine kinase inhibitor (TKI) sorafenib [4]. Recently, several TKIs for the …

… and epithelial-mesenchymal transition (EMT) in HCC [15]. … confer tumor resistance to
multiple agents such as sorafenib; … of HCC, blocking tumor-infiltrating macrophage-mediated …

… M2 macrophage-mediated miR-149-5p inhibition and accelerated MMP-9 expression in …
observed to confer significant tumor resistance to sorafenib by secreting hepatocyte growth …

… for the treatment of advanced HCC. Sorafenib was the first treatment approved for HCC [6]
and … as the vascular endothelial growth factor (VEGF) inhibitor [10]. Importantly, during the last …

… and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC),
sorafenib is … cells and induced epithelial–mesenchymal transition (EMT) through miR-128/CD151 …

… metastasis and epithelial-mesenchymal transition (EMT) 7 - 9 . Though it has reported that
… drugs aiming hypoxia like CCR4 inhibitors under sorafenib treatment background 79 . As …

… of ferroptosis in hepatoma cells and human hepatocellular carcinoma (HCC) cases. Patients
with low to moderate activation of ferroptosis in tumors had the highest risk of recurrence …

… for the treatment of HCC. In one such … sorafenib has demonstrated increased apoptosis of
tumor cells and elevated levels of M1-like macrophages, while simultaneously reducing tumor …